{"name":"Intergroupe Francophone de Cancerologie Thoracique","slug":"intergroupe-francophone-de-cancerologie-thoracique","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Customized Treatment","genericName":"Customized Treatment","slug":"customized-treatment","indication":"Thoracic malignancies (lung cancer and related thoracic tumors)","status":"marketed"},{"name":"Chemotherapy with platine","genericName":"Chemotherapy with platine","slug":"chemotherapy-with-platine","indication":"Lung cancer (thoracic malignancies)","status":"phase_3"},{"name":"Gemcitabine alone","genericName":"Gemcitabine alone","slug":"gemcitabine-alone","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Paclitaxel + Carboplatine","genericName":"Paclitaxel + Carboplatine","slug":"paclitaxel-carboplatine","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Pembrolizumab after randomization","genericName":"Pembrolizumab after randomization","slug":"pembrolizumab-after-randomization","indication":"Non-small cell lung cancer","status":"phase_2"}]}],"pipeline":[{"name":"Customized Treatment","genericName":"Customized Treatment","slug":"customized-treatment","phase":"marketed","mechanism":"Customized Treatment refers to personalized therapeutic approaches tailored to individual patient tumor characteristics and molecular profiles in thoracic oncology.","indications":["Thoracic malignancies (lung cancer and related thoracic tumors)"],"catalyst":""},{"name":"Chemotherapy with platine","genericName":"Chemotherapy with platine","slug":"chemotherapy-with-platine","phase":"phase_3","mechanism":"Platinum-based chemotherapy agents form DNA crosslinks that prevent cancer cell replication and induce apoptosis.","indications":["Lung cancer (thoracic malignancies)","Various solid tumors (as part of combination chemotherapy regimens)"],"catalyst":""},{"name":"Gemcitabine alone","genericName":"Gemcitabine alone","slug":"gemcitabine-alone","phase":"phase_3","mechanism":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.","indications":["Non-small cell lung cancer","Pancreatic cancer","Bladder cancer","Breast cancer","Ovarian cancer"],"catalyst":""},{"name":"Paclitaxel + Carboplatine","genericName":"Paclitaxel + Carboplatine","slug":"paclitaxel-carboplatine","phase":"phase_3","mechanism":"Paclitaxel and carboplatin work synergistically to kill cancer cells by stabilizing microtubules and causing DNA damage, respectively.","indications":["Non-small cell lung cancer (NSCLC)","Ovarian cancer","Breast cancer","Other solid tumors"],"catalyst":""},{"name":"Pembrolizumab after randomization","genericName":"Pembrolizumab after randomization","slug":"pembrolizumab-after-randomization","phase":"phase_2","mechanism":"PD-1 inhibitor","indications":["Non-small cell lung cancer","Head and neck squamous cell carcinoma","Melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQY20xUElOVjYxMjRlMDFqQkktODRIMWtFU0g3VUIxQWk0ei1wOHlKdnhVWXJKWDRNaS1sSUduVnI3R0N2TkV1WE1ORmtMbEtUelZITWg4X0c5RkRyVHpZWmxkSTFWc29QajV2VHppU1NncHhYLTdWWGJ0eUVkby1MYm82bVllUG1uVlVSakFSazRmQVJjaklDeUJKMA?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+ - openPR.com","headline":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYTd0NFdGd3cyMFpTbHlrVFd3TmNncV9qTGlQaHQ3WklxN1RDSHNRbkZPOURyVThuM0pibjZiTDVSeEtJUW9jbDZ5QVpFbVVyMm5vc05UbnVQWXIzemlpRjI1UktpaGRYZkRwWWhvUmd5SmF1V3VwcVBOWWxJLXV3QTZLM1JYNHI2dkY0?oc=5","date":"2025-06-24","type":"trial","source":"The Lancet","summary":"Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria","headline":"Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 1","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":1,"phase_3":3,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}